Virtu Financial LLC Makes New Investment in Hims & Hers Health, Inc. $HIMS

Virtu Financial LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 59,648 shares of the company’s stock, valued at approximately $1,937,000.

Several other hedge funds have also modified their holdings of HIMS. Farallon Capital Management LLC grew its position in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. Norges Bank acquired a new position in Hims & Hers Health in the 4th quarter worth about $62,153,000. Invesco Ltd. raised its holdings in Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the period. Clear Street Group Inc. purchased a new position in Hims & Hers Health during the third quarter worth approximately $87,372,000. Finally, Marex Group plc boosted its position in Hims & Hers Health by 162.2% during the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after purchasing an additional 1,496,707 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on HIMS shares. UBS Group set a $23.00 price objective on Hims & Hers Health in a report on Friday, May 22nd. Leerink Partners upped their target price on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research note on Monday, March 16th. Truist Financial increased their target price on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group set a $32.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $29.37.

Hims & Hers Health Trading Down 0.1%

Shares of Hims & Hers Health stock opened at $35.44 on Friday. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The firm has a market capitalization of $8.20 billion, a PE ratio of -393.79, a P/E/G ratio of 50.70 and a beta of 2.37. The firm’s 50-day moving average price is $26.74 and its 200 day moving average price is $26.64.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter last year, the firm posted $0.20 earnings per share. Hims & Hers Health’s quarterly revenue was up 3.8% on a year-over-year basis. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.05 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 9,463 shares of the stock in a transaction on Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the transaction, the insider directly owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. This represents a 3.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 4,490 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $141,435.00. Following the completion of the transaction, the insider owned 6,790 shares in the company, valued at $213,885. The trade was a 39.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 122,050 shares of company stock valued at $3,409,540. Insiders own 11.76% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.